Nature Communications (Feb 2019)
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
- Heidi M. Haikala,
- Johanna M. Anttila,
- Elsa Marques,
- Tiina Raatikainen,
- Mette Ilander,
- Henna Hakanen,
- Hanna Ala-Hongisto,
- Mariel Savelius,
- Diego Balboa,
- Bjoern Von Eyss,
- Vilja Eskelinen,
- Pauliina Munne,
- Anni I. Nieminen,
- Timo Otonkoski,
- Julia Schüler,
- Teemu D. Laajala,
- Tero Aittokallio,
- Harri Sihto,
- Johanna Mattson,
- Päivi Heikkilä,
- Marjut Leidenius,
- Heikki Joensuu,
- Satu Mustjoki,
- Panu Kovanen,
- Martin Eilers,
- Joel D. Leverson,
- Juha Klefström
Affiliations
- Heidi M. Haikala
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Johanna M. Anttila
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Elsa Marques
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Tiina Raatikainen
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Mette Ilander
- Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center
- Henna Hakanen
- Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center
- Hanna Ala-Hongisto
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Mariel Savelius
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Diego Balboa
- Research Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki
- Bjoern Von Eyss
- Leibniz Institute of Age Research, Fritz Lipmann Institute e.V
- Vilja Eskelinen
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Pauliina Munne
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- Anni I. Nieminen
- Department of Biosciences and Institute of Biotechnology, University of Helsinki
- Timo Otonkoski
- Research Programs Unit/Molecular Neurology, Biomedicum Stem Cell Center, University of Helsinki
- Julia Schüler
- Oncotest GmbH, (Now part of Charles River Laboratories Inc, 251 Ballardvale St, Wilmington, MA 01887, USA)
- Teemu D. Laajala
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Tero Aittokallio
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki
- Harri Sihto
- Research Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki
- Johanna Mattson
- Department of Oncology, University of Helsinki and Helsinki University Hospital
- Päivi Heikkilä
- Department of Pathology, University of Helsinki and Helsinki University Hospital
- Marjut Leidenius
- Breast Surgery Unit, Helsinki University Hospital
- Heikki Joensuu
- Research Programs Unit / Translational Cancer Biology & Medicum, University of Helsinki
- Satu Mustjoki
- Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center
- Panu Kovanen
- Department of Pathology, HUSLAB and Haartman Institute, University of Helsinki and Helsinki University Hospital
- Martin Eilers
- Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Würzburg
- Joel D. Leverson
- Oncology Development, AbbVie, Inc.
- Juha Klefström
- Cancer Cell Circuitry Laboratory, Research Programs Unit/Translational Cancer Biology and Medicum, University of Helsinki
- DOI
- https://doi.org/10.1038/s41467-019-08541-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 17
Abstract
Elevated MYC levels can sensitize tumor cells to apoptosis. In this study, the authors demonstrate that AMPK activation and BCL-2/BCL-XL inhibition have a synergistic effect on apoptosis, and that together with anti PD-1 therapy they can suppress Myc-driven mammary tumor growth.
